376584-20-2

Upstream product

• 564462-33-5 (4-Fluoro-phenyl)-acetic acid (E)-3-(3,4-difluoro-phenyl)-allyl ester 

Downstream Products

• 564462-36-8 (2S,3R)-3-(3,4-Difluorophenyl)-2-(4-fluorophenyl)-4-hydroxy-N-((3S)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-butyramide 
• 564462-34-6 3-(3,4-difluoro-phenyl)-2-(4-fluoro-phenyl)-4-hydroxy-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-butyramide 
• 376582-47-7 4-bromo-3-(3,4-difluoro-phenyl)-2-(4-fluoro-phenyl)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-butyramide 
• 1027923-77-8 (2S,3R)-3-(3,4-Difluoro-phenyl)-2-(4-fluoro-phenyl)-5-hydroxy-pentanoic acid benzyl ester 
• 376584-21-3 3-(3,4-difluoro-phenyl)-2-(4-fluoro-phenyl)-pent-4-enoic acid (1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide 

Relevant academic research and scientific papers

Design and synthesis of highly potent benzodiazepine γ-secretase inhibitors: Preparation of (2S,3R)-3-(3,4- difluorophenyl)-2-(4-fluorophenyl)-4-hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an as

Novel benzodiazepine-containing γ-secretase inhibitors for potential use in Alzheimer's disease have been designed that incorporate a substituted hydrocinnamide C-3 side chain. A syn combination of α-alkyl or aryl and β-hydroxy or hydroxymethyl substituen